ACAD ACADIA PHARMACEUTICALS INC

Nasdaq acadia-pharm.com


$ 20.88 $ 0.27 (1.31 %)    

Friday, 17-Oct-2025 15:59:59 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 20.89
$ 20.46
$ 20.00 x 101
$ 21.17 x 2
$ 20.33 - $ 21.07
$ 13.40 - $ 26.65
2,115,920
na
3.52B
$ 0.68
$ 15.86
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-04-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-04-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 02-28-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 acadia-pharmaceuticals-to-present-acp-711-and-acp-204-updates-nuplazid-analysis-at-2025-international-parkinsons-congress-october-5-9-2025

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced one late-breaker oral platform presentation and two poster presentati...

 beyond-the-numbers-11-analysts-discuss-acadia-pharmaceuticals-stock

In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide a...

 jp-morgan-maintains-overweight-on-acadia-pharmaceuticals-lowers-price-target-to-33

JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ: ACAD) with a Overweight and lowers the price target...

 needham-maintains-buy-on-acadia-pharmaceuticals-lowers-price-target-to-28

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30 to ...

 acadia-pharma-faces-trial-setback-as-prader-willi-syndrome-trial-falls-short

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales...

 acadias-phase-3-compass-pws-trial-of-intranasal-carbetocin-fails-to-meet-primary-endpoint-in-prader-willi-hyperphagia

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the ef...

 acadia-pharma-announces-publication-of-interim-results-from-lotus-study-on-daybue-for-rett-syndrome-in-developmental-medicine-and-child-neurology-journal

-- Findings reinforce efficacy and tolerability profile in patients prescribed DAYBUE in the U.S. for as long as 12 months, con...

 td-cowen-maintains-buy-on-acadia-pharmaceuticals-raises-price-target-to-39

TD Cowen analyst Ritu Baral maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 t...

 ubs-maintains-buy-on-acadia-pharmaceuticals-raises-price-target-to-39

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $36 to ...

 ubs-maintains-buy-on-acadia-pharmaceuticals-raises-price-target-to-36

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $32 to ...

 goldman-sachs-maintains-sell-on-acadia-pharmaceuticals-raises-price-target-to-17

Goldman Sachs analyst Salveen Richter maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Sell and raises the price target...

 rbc-capital-maintains-outperform-on-acadia-pharmaceuticals-raises-price-target-to-40

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price tar...

 jmp-securities-maintains-market-outperform-on-acadia-pharmaceuticals-raises-price-target-to-38

JMP Securities analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and raises th...

 mizuho-maintains-neutral-on-acadia-pharmaceuticals-raises-price-target-to-24

Mizuho analyst Uy Ear maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $23 to ...

 acadia-pharmaceuticals-raises-fy2025-sales-guidance-from-1030b-1095b-to-1045b-1095b-vs-1064b-est

ACADIA Pharmaceuticals (NASDAQ:ACAD) raises FY2025 sales outlook from $1.030 billion-$1.095 billion to $1.045 billion-$1.095 bi...

 acadia-pharmaceuticals-q2-eps-016-beats-013-estimate-sales-264566m-beat-262414m-estimate

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION